BRIEF-Roivant Announces Topline Results From Proof-Of-Concept Study Of Imvt-1402 In Cutaneous Lupus Erythematosus
Reuters2026/09/23 11:04Roivant Sciences Ltd ROIV.O:
ROIVANT ANNOUNCES TOPLINE RESULTS FROM PROOF-OF-CONCEPT STUDY OF IMVT-1402 IN CUTANEOUS LUPUS ERYTHEMATOSUS
ROIVANT SCIENCES - IMVT-1402 STUDY IN CLE DID NOT ACHIEVE STATISTICAL SIGNIFICANCE ON PRIMARY ENDPOINT
ROIVANT SCIENCES - IMMUNOVANT TO STOP DEVELOPMENT OF IMVT-1402 IN CLE
ROIVANT SCIENCES - IMVT-1402 DEMONSTRATES FAVORABLE SAFETY AND TOLERABILITY PROFILE
ROIVANT SCIENCES - ALL OTHER CLINICAL DEVELOPMENT TIMELINES REMAIN ON TRACK
Source text: ID:nGNX559XzF
Further company coverage: ROIV.O
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Madagascar villagers file claim against Rio Tinto over alleged mine contamination
BUZZ-Firefly signs payload agreement with Starcloud; stock price rises
BUZZ-United Therapeutics shares soar after winning lawsuit against Liquidia
Crypto prices
More
